相似文献
1
RAS-MAPK signaling influences the efficacy of ALK-targeting agents in lung cancer.
Mol Cell Oncol. 2015 Oct 29;3(2):e1091061. doi: 10.1080/23723556.2015.1091061. eCollection 2016 Mar.
2
RAS-MAPK in ALK targeted therapy resistance.
Cell Cycle. 2015;14(23):3661-2. doi: 10.1080/15384101.2015.1096103.
3
RAS signaling in ALK fusion lung cancer.
Small GTPases. 2016;7(1):32-3. doi: 10.1080/21541248.2015.1131803. Epub 2016 Feb 22.
4
MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Sci Signal. 2017 Nov 28;10(507):eaam7550. doi: 10.1126/scisignal.aam7550.
5
Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
Pharmacol Res. 2017 Mar;117:343-356. doi: 10.1016/j.phrs.2017.01.007. Epub 2017 Jan 8.
6
Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.
Pharmacol Res. 2013 Feb;68(1):68-94. doi: 10.1016/j.phrs.2012.11.007. Epub 2012 Nov 28.
7
The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
Mol Cancer. 2018 Feb 19;17(1):52. doi: 10.1186/s12943-018-0810-4.
8
Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer.
Adv Exp Med Biol. 2016;893:179-187. doi: 10.1007/978-3-319-24223-1_9.
9
Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Oncol Res Treat. 2019;42(11):599-606. doi: 10.1159/000502755. Epub 2019 Sep 17.
10
Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Respir Investig. 2014 Nov;52(6):330-8. doi: 10.1016/j.resinv.2014.06.005. Epub 2014 Jul 30.
引用本文的文献
1
A radiologist's guide to novel anticancer therapies in the era of precision medicine.
Eur J Radiol Open. 2022 Mar 2;9:100406. doi: 10.1016/j.ejro.2022.100406. eCollection 2022.
2
Different driver gene mutations in patients with synchronous multiple primary lung cancers: a case report.
J Cardiothorac Surg. 2020 Jul 29;15(1):196. doi: 10.1186/s13019-020-01178-z.
3
Involvement of the long noncoding RNA NEAT1 in carcinogenesis.
Mol Oncol. 2019 Jan;13(1):46-60. doi: 10.1002/1878-0261.12404. Epub 2018 Dec 3.
4
LncRNA NEAT1/let-7a-5p axis regulates the cisplatin resistance in nasopharyngeal carcinoma by targeting Rsf-1 and modulating the Ras-MAPK pathway.
Cancer Biol Ther. 2018 Jun 3;19(6):534-542. doi: 10.1080/15384047.2018.1450119. Epub 2018 Apr 9.
本文引用的文献
1
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.
Nat Med. 2015 Sep;21(9):1038-47. doi: 10.1038/nm.3930. Epub 2015 Aug 24.
2
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
N Engl J Med. 2014 Nov 13;371(20):1877-88. doi: 10.1056/NEJMoa1406037. Epub 2014 Sep 29.
3
Comprehensive molecular profiling of lung adenocarcinoma.
Nature. 2014 Jul 31;511(7511):543-50. doi: 10.1038/nature13385. Epub 2014 Jul 9.
4
Ceritinib in ALK-rearranged non-small-cell lung cancer.
N Engl J Med. 2014 Mar 27;370(13):1189-97. doi: 10.1056/NEJMoa1311107.
5
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
N Engl J Med. 2013 Jun 20;368(25):2385-94. doi: 10.1056/NEJMoa1214886. Epub 2013 Jun 1.
6
Circumventing cancer drug resistance in the era of personalized medicine.
Cancer Discov. 2012 Mar;2(3):214-26. doi: 10.1158/2159-8290.CD-12-0012. Epub 2012 Feb 28.
7
Lessons learned from the development of kinase inhibitors.
Clin Adv Hematol Oncol. 2009 Sep;7(9):588-9.
Zotero 插件